Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)

Revenue by Segment

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Medical Diagnostics and Treatments	12.55M	14.67M	15.43M	13.49M	12.92M
Medical Diagnostics and Treatments Growth	-14.45%	-4.93%	14.42%	4.41%	-
Radiation Therapy and Medical Oncology Services	3.16M	1.97M	800.88K	321.13K	-
Radiation Therapy and Medical Oncology Services Growth	59.88%	146.57%	149.40%	-	-
Total	15.71M	16.65M	16.23M	13.81M	12.92M
Total Growth	-5.63%	2.54%	17.56%	6.90%	-

Revenue by Geography

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Singapore	15.71M	16.65M	16.23M	13.81M	12.92M
Singapore Growth	-5.63%	2.54%	17.56%	6.90%	-
Total	15.71M	16.65M	16.23M	13.81M	12.92M
Total Growth	-5.63%	2.54%	17.56%	6.90%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 3, 2026

Data Sources Report a data error